Cargando…
Effect of Dexmedetomidine for Palliative Sedation for Refractory Dyspnoea in Patients with Terminal-Stage Cancer
BACKGROUND: Dyspnoea affects a considerable percentage of patients with terminal-stage cancer, and clinical guidelines recommend palliative sedation for patients with refractory dyspnoea. Midazolam is currently the most commonly used sedative; however, it can cause serious adverse reactions, such as...
Autores principales: | Li, Na, Cui, Meng, Wang, Yumei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040164/ https://www.ncbi.nlm.nih.gov/pubmed/36987523 http://dx.doi.org/10.2147/CMAR.S404934 |
Ejemplares similares
-
Dexmedetomidine sedation in ICU
por: Yu, Soo-Bong
Publicado: (2012) -
Sedative and Immunosuppressive Effects of Dexmedetomidine in Transplantation
por: Lee, Chen-Fang, et al.
Publicado: (2021) -
Different effects of propofol and dexmedetomidine sedation on electroencephalogram patterns: Wakefulness, moderate sedation, deep sedation and recovery
por: Xi, Chunhua, et al.
Publicado: (2018) -
Palliative sedation for terminally ill cancer patients in a tertiary cancer center in Shanghai, China
por: Gu, Xiaoli, et al.
Publicado: (2015) -
Effectiveness of Morphine in Managing Refractory Dyspnoea in Patients with Coronavirus Disease (COVID-19)
por: Sirohiya, Prashant, et al.
Publicado: (2022)